Vestal Point Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Vestal Point Capital’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,000	Closed	-$5.02M	–	76
2025 Q1	$5.02M	Buy	200,000 +20,000	+11%	+$505K	0.36%	45
2024 Q4	$4.95M	Hold	180,000	–	–	0.29%	53
2024 Q3	$5.18M	Hold	180,000	–	–	0.39%	47
2024 Q2	$4.46M	Buy	180,000 +50,000	+38%	+$1.42M	0.33%	46
2024 Q1	$4.19M	Hold	130,000	–	–	0.35%	47
2023 Q4	$5.28M	Buy	+130,000	New	+$4.78M	0.56%	32

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vestal Point Capital's LKFT Position: Q2 2025 in Review

Vestal Point Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 200,000 shares — an estimated $5.02M sold.

Vestal Point Capital first reported a position in LKFT in Q4 2023 and held it in 6 quarters. The position peaked at $5.28M in Q4 2023. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

Vestal Point Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
Vestal Point Capital sold 200,000 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $5.02M.
Vestal Point Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2023 and held it in 6 quarters.
Vestal Point Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.28M in Q4 2023.
85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.